Guo-Fu Li

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 22

Top Topics

Bone Mineral Density

Metastatic Breast Cancer

Top Venues

European journal of drug metabolism and pharmacokinetics

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

European journal of clinical pharmacology

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Yu-Wei Qiao, Guo Yu, Guo-Fu Li
Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail. Clinical drug investigation (2024)
Yu-Wei Qiao, Guo Yu, Guo-Fu Li
Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail. Clinical drug investigation 44 (6) (2024)
Yang Yu, Guo-Fu Li, Jian Li, Lu-Yao Han, Zhi-Long Zhang, Tian-Shuo Liu, Shu-Xin Jiao, Yu-Wei Qiao, Na Zhang, De-Chuan Zhan, Shao-Qiu Tang, Guo Yu
Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence. Expert review of anti-infective therapy (2024)
Guo-Fu Li, Yu-Wei Qiao, Ai-Jia Guan, Guo Yu
Informative Censoring of Progression-Free Survival Data in TROPiCS-02 Trial: An Unrecognized Bias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Guo Yu, Na Zhang, Ai-Jia Guan, Yu-Wei Qiao, Guo-Fu Li
Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Guo-Fu Li, Yu-Wei Qiao, Ai-Jia Guan, Guo Yu
Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Danna Wu, Guo-Fu Li
Improving Report of ADAURA Trial by Distinguishing Treatment-Related Adverse Events From Treatment-Emergent Adverse Events and Assessing Independence of Censoring in Final Disease-Free Survival Analyses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Xiang Chen, Guo Yu, Guo-Fu Li
Use of Clearance Concepts to Simulate Impact of Interleukin-6 on Drug Elimination Governed by Cytochromes P450 3A4 and Glomerular Filtration Rate. European journal of drug metabolism and pharmacokinetics (2023)
Guo-Fu Li, Yu-Wei Qiao, Ai-Jia Guan, Guo Yu
Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Dan-Na Wu, Guo Yu, Guo-Fu Li
Reproducing prolonged time to peak bisoprolol concentration by PBPK modeling with lysosomal trapping in enterocytes. CPT: pharmacometrics & systems pharmacology 11 (1) (2022)
Dan-Na Wu, Li-Rong Jiao, Guo-Fu Li, Guo Yu
Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19. European journal of clinical pharmacology 78 (8) (2022)
Yichao Yu, Qi-Qi Zhao, Guo-Fu Li
Prediction of Non-Linear Pharmacokinetics of Monoclonal Antibodies in Human from Nonclinical Data: Are We There Yet? European journal of drug metabolism and pharmacokinetics 46 (4) (2021)
Dan-Na Wu, Guo-Fu Li, Guo Yu
Use of proton pump inhibitors and adverse clinical outcomes. British journal of clinical pharmacology 88 (5) (2021)
Xiao-Xiao An, Yichao Yu, Guo-Fu Li, Guo Yu
Abundance and Associated Variations of Cytochrome P450 Drug-Metabolizing Enzymes in the Liver of East Asian Adults: A Meta-Analysis. European journal of drug metabolism and pharmacokinetics 46 (2) (2021)
Guo-Fu Li, Xiao-Xiao An, Yichao Yu, Li-Rong Jiao, Daniele Canarutto, Guo Yu, Guangji Wang, Dan-Na Wu, Yin Xiao
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut 70 (9) (2020)
Jia-Qin Gu, Yun-Peng Guo, Zheng Jiao, Jun-Jie Ding, Guo-Fu Li
How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective. European journal of drug metabolism and pharmacokinetics 45 (2) (2020)
Guo Yu, Guo-Fu Li
Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective. European journal of drug metabolism and pharmacokinetics 45 (1) (2020)
Guo-Fu Li, Qing-Shan Zheng, Yichao Yu, Wei Zhong, Hong-Hao Zhou, Furong Qiu, Guangji Wang, Guo Yu, Hartmut Derendorf
Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults. Clinical pharmacokinetics 58 (7) (2020)
Junyi Wu, Chen Wang, Guo-Fu Li, En-Tzu Tang, Qingshan Zheng
Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: A model-based meta-analysis. British journal of clinical pharmacology 87 (3) (2020)
Jun-Yi Wu, Guo Yu, Guo-Fu Li
Model-Informed Approaches for Alternative Aripiprazole Dosing Regimens and Missed Dose Management: Towards Better Adherence to Antipsychotic Pharmacotherapy. European journal of drug metabolism and pharmacokinetics 43 (4) (2019)
Guo Yu, Dan-Na Wu, Yan Gong, Guo-Fu Li, Hong-Hao Zhou
Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? European journal of clinical pharmacology 74 (6) (2018)
Guo Yu, Hong-Hao Zhou, Qing-Shan Zheng, Guo-Fu Li
Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese. European journal of clinical pharmacology 75 (4) (2018)